Phosphodiesterase sequence variants may predispose to prostate cancer.

We hypothesized that mutations that inactivate phosphodiesterase (PDE) activity and lead to increased cAMP and cyclic guanosine monophosphate levels may be associated with prostate cancer (PCa). We sequenced the entire PDE coding sequences in the DNA of 16 biopsy samples from PCa patients. Novel mutations were confirmed in the somatic or germline state by Sanger sequencing. Data were then compared to the 1000 Genome Project. PDE, CREB and pCREB protein expression was also studied in all samples, in both normal and abnormal tissue, by immunofluorescence. We identified three previously described PDE sequence variants that were significantly more frequent in PCa. Four novel sequence variations, one each in the PDE4B,PDE6C, PDE7B and PDE10A genes, respectively, were also found in the PCa samples. Interestingly, PDE10A and PDE4B novel variants that were present in 19 and 6% of the patients were found in the tumor tissue only. In patients carrying PDE defects, there was pCREB accumulation (P<0.001), and an increase of the pCREB:CREB ratio (patients 0.97±0.03; controls 0.52±0.03; P-value <0.001) by immunohistochemical analysis. We conclude that PDE sequence variants may play a role in the predisposition and/or progression to PCa at the germline and/or somatic state respectively.

[1]  W. Chiu,et al.  Extension of anisotropic effective medium theory to account for an arbitrary number of inclusion types , 2015 .

[2]  N. Niikawa,et al.  Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis. , 2014, Cellular signalling.

[3]  F. Faucz,et al.  Clinical and molecular genetics of the phosphodiesterases (PDEs). , 2014, Endocrine reviews.

[4]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[5]  J. Zhang,et al.  Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice , 2014, Neuroscience.

[6]  D. Carraro,et al.  Biobanking practice: RNA storage at low concentration affects integrity. , 2014, Biopreservation and biobanking.

[7]  G. Jenster,et al.  The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells , 2014, British Journal of Cancer.

[8]  Klodiana Kolomitro,et al.  Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer , 2013, World Journal of Urology.

[9]  K. Sugihara,et al.  67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. , 2013, The Journal of clinical investigation.

[10]  T. Murata,et al.  Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells , 2013, Oncology reports.

[11]  K. Scott Coffield,et al.  Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis. , 2013, Asian journal of andrology.

[12]  Hong Wang,et al.  Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor? , 2013, The Journal of clinical investigation.

[13]  M. Sudol,et al.  Modularity and functional plasticity of scaffold proteins as p(l)acemakers in cell signaling. , 2012, Cellular signalling.

[14]  J. Bertherat,et al.  Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors. , 2012, The Journal of clinical endocrinology and metabolism.

[15]  F. Faucz,et al.  Identification of novel genetic variants in phosphodiesterase 8B ( PDE8B ), a cAMP‐specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours , 2012, Clinical endocrinology.

[16]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[17]  T. Uchiumi,et al.  Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer , 2012, The Prostate.

[18]  Jiang-feng Du,et al.  Inhibitory Effects and Underlying Mechanism of 7-Hydroxyflavone Phosphate Ester in HeLa Cells , 2012, PloS one.

[19]  Diogo F. C. Patrão,et al.  The value of a tumor bank in the development of cancer research in Brazil: 13 years of experience at the a C camargo hospital. , 2012, Biopreservation and biobanking.

[20]  F. Pagani,et al.  An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects , 2012, Human molecular genetics.

[21]  C. Cheadle,et al.  Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations. , 2012, The Journal of clinical endocrinology and metabolism.

[22]  Frank Schwede,et al.  Activation of PDE10 and PDE11 Phosphodiesterases* , 2011, The Journal of Biological Chemistry.

[23]  Claire Lugnier,et al.  Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. , 2011, Molecular nutrition & food research.

[24]  T. L. Mazzuco,et al.  Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations. , 2011, The Journal of clinical endocrinology and metabolism.

[25]  F. Faucz,et al.  Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[26]  F. Faucz,et al.  Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. , 2011, The Journal of clinical endocrinology and metabolism.

[27]  D. Merkle,et al.  Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. , 2011, Cellular signalling.

[28]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[29]  V. Bours,et al.  The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes , 2010, Clinical genetics.

[30]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[31]  S. Washington,et al.  A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy , 2010, Drug design, development and therapy.

[32]  H. Parkinson,et al.  A global map of human gene expression , 2010, Nature Biotechnology.

[33]  E. Remmers,et al.  Mutations and polymorphisms in the gene encoding regulatory subunit type 1‐alpha of protein kinase A (PRKAR1A): an update , 2010, Human mutation.

[34]  H. Klocker,et al.  Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP‐dependent protein kinase A , 2010, International journal of cancer.

[35]  Chunyu Wang Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia , 2010, Current opinion in urology.

[36]  Wei Zhang,et al.  Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G , 2009, Molecular Cancer Therapeutics.

[37]  D. Schadendorf,et al.  cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells , 2009, Cellular and Molecular Life Sciences.

[38]  Mohammed T Ansari,et al.  Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis , 2009, Annals of Internal Medicine.

[39]  Y. Nakamura,et al.  Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways , 2009, Oncogene.

[40]  M. Greene,et al.  Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. , 2009, Cancer research.

[41]  Yun Liu,et al.  LS-SNP/PDB: annotated non-synonymous SNPs mapped to Protein Data Bank structures , 2009, Bioinform..

[42]  G. Lin,et al.  Lack of direct androgen regulation of PDE5 expression. , 2009, Biochemical and biophysical research communications.

[43]  J. Maguire,et al.  Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.

[44]  N. Lawrentschuk,et al.  Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds , 2009, Current opinion in urology.

[45]  D. Halpin ABCD of the phosphodiesterase family: interaction and differential activity in COPD , 2008, International journal of chronic obstructive pulmonary disease.

[46]  Christian von Mering,et al.  STRING 8—a global view on proteins and their functional interactions in 630 organisms , 2008, Nucleic Acids Res..

[47]  M. Pal,et al.  Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. , 2008, Journal of medicinal chemistry.

[48]  Alexandra M. E. Jones,et al.  Broccoli Consumption Interacts with GSTM1 to Perturb Oncogenic Signalling Pathways in the Prostate , 2008, PloS one.

[49]  J. Bertherat,et al.  Phosphodiesterase 11A (PDE11A) and Genetic Predisposition to Adrenocortical Tumors , 2008, Clinical Cancer Research.

[50]  I. Bossis,et al.  Phosphodiesterase 11A Expression in the Adrenal Cortex, Primary Pigmented Nodular Adrenocortical Disease, and other Corticotropin-independent Lesions , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[51]  E. Remmers,et al.  Large Deletions of the PRKAR1A Gene in Carney Complex , 2008, Clinical Cancer Research.

[52]  D. Burstein,et al.  Large-scale comparative analysis of splicing signals and their corresponding splicing factors in eukaryotes. , 2007, Genome research.

[53]  Li Ma,et al.  Mitogen-activated Protein Kinase p38 Regulates the Wnt/Cyclic GMP/Ca2+ Non-canonical Pathway* , 2007, Journal of Biological Chemistry.

[54]  Lise Getoor,et al.  SplicePort—An interactive splice-site analysis tool , 2007, Nucleic Acids Res..

[55]  P. Kochunov,et al.  Akt/cAMP-Responsive Element Binding Protein/Cyclin D1 Network: A Novel Target for Prostate Cancer Inhibition in Transgenic Adenocarcinoma of Mouse Prostate Model Mediated by Nexrutine, a Phellodendron Amurense Bark Extract , 2007, Clinical Cancer Research.

[56]  W. Sessa,et al.  The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway , 2007, Journal of cellular physiology.

[57]  P. Gregersen,et al.  Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. , 2006, Cancer research.

[58]  P. Sandner,et al.  Pre‐clinical evidence for the use of phosphodiesterase‐5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms , 2006, BJU international.

[59]  I. Bossis,et al.  A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia , 2006, Nature Genetics.

[60]  H. Tillmanns,et al.  Role of cGMP in Sildenafil-Induced Activation of Endothelial Ca(2+)-Activated K(+) Channels , 2006, Journal of cardiovascular pharmacology.

[61]  Antonio Marín,et al.  Characterization and prediction of alternative splice sites. , 2006, Gene.

[62]  C. Stratakis,et al.  Serial analysis of gene expression in adrenocortical hyperplasia caused by a germline PRKAR1A mutation. , 2006, The Journal of clinical endocrinology and metabolism.

[63]  D. Campbell,et al.  Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. , 2005, The Biochemical journal.

[64]  G. Morelli,et al.  Inhibition of phosphodiesterase 11 (PDE11) impacts on sperm quality , 2005, International Journal of Impotence Research.

[65]  R. Weiss,et al.  Regulation of cyclic nucleotides in the urinary tract. , 2005, Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.

[66]  B. Zhu,et al.  Suppression of cyclic GMP‐specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells , 2005, Journal of cellular biochemistry.

[67]  Hsien-yu Wang,et al.  PDE6 is an effector for the Wnt/Ca2+/cGMP-signalling pathway in development. , 2004, Biochemical Society transactions.

[68]  R. Cote Characteristics of Photoreceptor PDE (PDE6): similarities and differences to PDE5 , 2004, International Journal of Impotence Research.

[69]  Francisco E. Baralle,et al.  Genomic variants in exons and introns: identifying the splicing spoilers , 2004, Nature Reviews Genetics.

[70]  J. Haynes,et al.  Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. , 2004, Cellular signalling.

[71]  H. Ke,et al.  Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. , 2003, Structure.

[72]  A. Sahu,et al.  A phosphatidylinositol 3-kinase–phosphodiesterase 3B–cyclic AMP pathway in hypothalamic action of leptin on feeding , 2002, Nature Neuroscience.

[73]  G. Baillie,et al.  Sub‐family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP‐specific phosphodiesterases , 2000, British journal of pharmacology.

[74]  G. Baillie,et al.  ERK2 Mitogen-activated Protein Kinase Binding, Phosphorylation, and Regulation of the PDE4D cAMP-specific Phosphodiesterases , 2000, The Journal of Biological Chemistry.

[75]  M. Fidock,et al.  Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. , 2000, Biochemical and biophysical research communications.

[76]  J. Beavo,et al.  Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[77]  J. Beavo,et al.  Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[78]  K. Fujishige,et al.  Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)* , 1999, The Journal of Biological Chemistry.

[79]  H. Granger,et al.  Protein Kinase G Mediates Vascular Endothelial Growth Factor-induced Raf-1 Activation and Proliferation in Human Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[80]  M. Houslay,et al.  cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. , 1998, The Biochemical journal.

[81]  David Haussler,et al.  Improved splice site detection in Genie , 1997, RECOMB '97.

[82]  Peter G. Korning,et al.  Splice Site Prediction in Arabidopsis Thaliana Pre-mRNA by Combining Local and Global Sequence Information , 1996 .

[83]  E. Arnold,et al.  Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. , 1994, The American journal of physiology.

[84]  J. Persson,et al.  Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancer. , 2014, Urologic oncology.

[85]  G. Jenster,et al.  The cAMP phosphodiesterase-4 D 7 ( PDE 4 D 7 ) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells , 2014 .

[86]  R. Ganapathi,et al.  Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs. , 2014, Urologic oncology.

[87]  Emily H Turner,et al.  Targeted Capture and Massively Parallel Sequencing of Twelve Human Exomes , 2009, Nature.

[88]  M. Saito,et al.  Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity. , 2008, Asian journal of andrology.

[89]  E. Degerman,et al.  Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. , 2001, Progress in nucleic acid research and molecular biology.

[90]  C. A. Thomas,et al.  Molecular cloning. , 1977, Advances in pathobiology.